Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 4/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9840655 | 0.91 | L3MBTL1 (0.49) | L3MBTL1MAOBKDM4EALDH1A1 | |
| SCHEMBL1097150 | 0.89 | L3MBTL1 (0.61) | L3MBTL1TDP1FFAR1MAOBMRGPRX4 | |
| SCHEMBL19243141 | 0.83 | MAOB (0.57) | L3MBTL1TDP1FFAR1MAOB | |
| SCHEMBL2174555 | 0.83 | L3MBTL1 (0.54) | L3MBTL1TDP1FFAR1MAOBMRGPRX4 | |
| SCHEMBL13518013 | 0.82 | MAOB (0.55) | L3MBTL1TDP1FFAR1MAOBALDH1A1 | |
| SCHEMBL1097812 | 0.81 | KMT2A (0.56) | ALDH1A1 | |
| SCHEMBL30343022 | 0.81 | MAOB (0.58) | L3MBTL1MAOBMRGPRX4KDM4EALDH1A1 | |
| SCHEMBL10373885 | 0.81 | MAOB (0.58) | L3MBTL1MAOBMRGPRX4KDM4EALDH1A1 | |
| SCHEMBL14970601 | 0.81 | KDM4E (0.60) | L3MBTL1TDP1KDM4EALDH1A1GAA | |
| SCHEMBL3716437 | 0.81 | TAS1R3 (0.53) | L3MBTL1TDP1FFAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973164-B2 | Quinoline derivatives | ASTRAZENECA AB (SE) | 2011-07-05 | — | — | US | disclosed |
| US-20090076074-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| EP-1994025-A1 | QUINOLINE DERIVATIVES | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007113548-A1 | NAPHTHYRIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007099326-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076074-A1 | QUINOLINE DERIVATIVES | RECQL, NQO2, CCNA1 | L3MBTL1 3797/4885TDP1 1898/4885FFAR1 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.